In a randomized multicenter therapeutic trial, 32 patients with erythema migrans received oral azithromycin 500 mg once daily and 33 patients received phenoxymethylpenicillin (penicillin V) 1 million U three times daily for 10 days. Follow-up was for a median of 17 (range 3-32) months. Four weeks after initiation of therapy, 20 (62%) patients given azithromycin and 17 (51%) patients given penicillin V were completely free of all signs and symptoms and did not develop new ones subsequently (no significant difference). Three months after initiation of therapy, the corresponding figures were 25 (78%) azithromycin and 28 (85%) penicillin V recipients (no significant difference). There were only minor sequelae such as arthralgia, headache, fatigue, stiff neck and dysesthesia. Azithromycin led to a significantly faster resolution of the erythema migrans than penicillin V (p < 0.001). Significantly more patients with more severe compared with mild initial disease had an elevated IgM antibody titer prior to therapy (p < 0.001). Usually mild to moderate side effects occurred in 12 patients given azithromycin and five patients given penicillin V (p < 0.05). Azithromycin appears to be as effective as penicillin V for the treatment of early Lyme borreliosis and it seems to clear the erythema migrans more promptly.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01728915 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling Lyme Neuroborreliosis in the Absence of Dermatological Symptoms.
Cureus
December 2024
Internal Medicine, Central Michigan University, Saginaw, USA.
Lyme neuroborreliosis can present with isolated neurological manifestations, posing diagnostic challenges, especially in the absence of hallmark dermatological symptoms like erythema migrans. This case highlights a patient with isolated cervical radiculopathy due to Lyme neuroborreliosis, presenting without systemic features such as fever, arthralgia, or rash. The diagnosis was confirmed through serological testing, with positive findings on the Western blot.
View Article and Find Full Text PDFDose Evaluation and Optimization of Amoxicillin in Children Treated for Lyme Disease.
J Clin Pharmacol
January 2025
Center for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Amoxicillin is commonly used to treat erythema migrans in the first stage of Lyme disease in children, with a recommended dose of 50 mg/kg/day, administered three times a day (q8h). This model-based simulation study aimed to determine whether splitting the same daily dose into two administrations (q12h) would provide comparable drug exposure. A pharmacokinetic model suitable for a pediatric population (age: 1 month to 18 years, weight: 4-80 kg) was selected through a literature review.
View Article and Find Full Text PDFIncreased usage of doxycycline for young children with Lyme disease.
Front Antibiot
May 2024
Division of Emergency Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.
Background: The 2018 Infectious Disease Committee of the American Academy of Pediatrics stated that up to 3 weeks or less of doxycycline is safe in children of all ages. Our goal was to examine trends in doxycycline treatment for children with Lyme disease.
Methods: We assembled a prospective cohort of children aged 1 to 21 years with Lyme disease who presented to one of eight participating Pedi Lyme Net centers between 2015 and 2023.
Lyme neuroborreliosis in Japan: Borrelia burgdorferi sensu lato as a cause of meningitis of previously undetermined etiology in hospitalized patients outside of the island of Hokkaido, 2010-2021.
Eur J Neurol
January 2025
Department of Clinical Laboratory and Internal Medicine, National Center of Neurology and Psychiatry, Tokyo, Japan.
Background And Purpose: Clinical manifestations of Lyme borreliosis (LB), caused by Borrelia burgdorferi sensu lato (Bbsl), include erythema migrans, Lyme neuroborreliosis (LNB), carditis, and arthritis. LB is a notifiable disease in Japan with <30 surveillance-reported LB cases annually, predominately from Hokkaido Prefecture. However, LB, including LNB, may be under-diagnosed in Japan since diagnostic tests are not readily available.
View Article and Find Full Text PDFIntermittent High-Degree AV Block, Rash, and Facial Droop with Negative Lyme PCR.
J Emerg Med
January 2025
Department of Emergency Medicine, University of Kentucky, Lexington, Kentucky.
Background: Lyme disease is the most common tick-borne illness in the United States, and cases of Lyme disease have nearly doubled since the early 2000s. Symptoms and presentation vary based on severity of illness, with more serious complications of disease consisting of neurologic and cardiac dysfunction. Testing is often unreliable, which can lead to delayed diagnosis and management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!